Pharmaceutical industry – Page 56
-
Business
AbbVie emerges from Abbott split
US healthcare giant Abbott has renamed the branded drugs part of its business
-
Business
GSK to build £350m factory in UK
GlaxoSmithKline (GSK) has announced £350 million plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria
-
News
GSK to build £350 million factory in UK
Tax breaks in the UK budget have prompted GSK to reaffirm its commitment
-
News
India green lights production of patented cancer drug
For the first time India has invoked a ‘compulsory licence’ clause to cut the cost of a patented anti-cancer drug
-
CareersThe future of medicine
A medicinal chemistry course that’s giving students a real taste of pharma - failure, frustration and all
-
OpinionThe elements of drug design
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
-
Opinion
The language of the lab
Derek Lowe wonders what the lab lingua franca might be in the years to come
-
Opinion
Rewards of repurposing
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
-
-
Opinion
Compounds in the dark
Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature
-
OpinionCommon sense and safety
You have to make space for good sense when thinking about safety, argues Derek Lowe
-
Opinion'Pay for delay'
Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
-
OpinionThe pitfalls that prevent progress
Derek Lowe highlights the less visible pitfalls on the road to a new drug
-
OpinionThe financial funfair
The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?
-
OpinionCategorising chemists
To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe
-
OpinionWho counts as a chemist?
The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country
-
OpinionThe return of the return of natural products
'Natural products are back!' is a headline Derek Lowe has seen several times before
-
OpinionThe risk vs reward of drug discovery
Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
-
OpinionElevating enzymes
Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential
-
OpinionFluorine fanatics
Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship